Archives of the Turkish Society of Cardiology
Clinical pharmacology of the apixaban and frequently asked questions about its clinical use [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2016; 44(2): 1-6

Clinical pharmacology of the apixaban and frequently asked questions about its clinical use

Adnan Abacı
Gazi Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara

Apixaban is a new, strong, reversible, competitive direct inhibitor of factor Xa. By inhibiting factor Xa, it prevents the conversion of prothrombin to thrombin. Large, randomized clinical trials showed that apixaban is superior to varfarin in the prevention of stroke in atrial fibrillation and caused less bleeding than varfarin. This article summarized clinical pharmacology of the apixaban and responded to frequently asked questions about it.

Keywords: Apixaban, reversible, competitive.

How to cite this article
Adnan Abacı. Clinical pharmacology of the apixaban and frequently asked questions about its clinical use. Turk Kardiyol Dern Ars. 2016; 44(2): 1-6

Corresponding Author: Adnan Abacı, Türkiye
© Copyright 2020 Archives of the Turkish Society of Cardiology
LookUs & Online Makale